Improvements in Systemic Therapies for Advanced Malignant Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best...

Descripción completa

Detalles Bibliográficos
Autores principales: Deiana, Chiara, Fabbri, Francesca, Tavolari, Simona, Palloni, Andrea, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342038/
https://www.ncbi.nlm.nih.gov/pubmed/37445594
http://dx.doi.org/10.3390/ijms241310415
_version_ 1785072406016032768
author Deiana, Chiara
Fabbri, Francesca
Tavolari, Simona
Palloni, Andrea
Brandi, Giovanni
author_facet Deiana, Chiara
Fabbri, Francesca
Tavolari, Simona
Palloni, Andrea
Brandi, Giovanni
author_sort Deiana, Chiara
collection PubMed
description Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.
format Online
Article
Text
id pubmed-10342038
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103420382023-07-14 Improvements in Systemic Therapies for Advanced Malignant Mesothelioma Deiana, Chiara Fabbri, Francesca Tavolari, Simona Palloni, Andrea Brandi, Giovanni Int J Mol Sci Review Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies. MDPI 2023-06-21 /pmc/articles/PMC10342038/ /pubmed/37445594 http://dx.doi.org/10.3390/ijms241310415 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Deiana, Chiara
Fabbri, Francesca
Tavolari, Simona
Palloni, Andrea
Brandi, Giovanni
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_full Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_fullStr Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_full_unstemmed Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_short Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_sort improvements in systemic therapies for advanced malignant mesothelioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342038/
https://www.ncbi.nlm.nih.gov/pubmed/37445594
http://dx.doi.org/10.3390/ijms241310415
work_keys_str_mv AT deianachiara improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT fabbrifrancesca improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT tavolarisimona improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT palloniandrea improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT brandigiovanni improvementsinsystemictherapiesforadvancedmalignantmesothelioma

Ejemplares similares